Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies

"Each subject will be infused with single dose of anti-CD19-CAR-T cells.~A classic 3+3 dose escalation will be employed."

Fludarabine will be given at a dose of 25 mg/m2/day intravenously (IV) for 3 days prior to anti-CD19-CAR-T cells infusion.

Cyclophosphamide will be given at a dose of 250 mg/m2/day intravenously (IV) for 3 days prior to anti-CD19-CAR-T cells infusion.